SAN JOSE, Calif.--(BUSINESS WIRE)--DFINE®, Inc., a fast-growing market leader in the treatment of spinal diseases, today announced the launch of www.spine-tumors.com, a new online resource created to educate patients about a minimally-invasive treatment option for severe pain due to metastatic spinal tumors.
Patients share their positive experiences with the STAR™ Tumor Ablation System and targeted radiofrequency ablation – typically an outpatient procedure for pain relief. The procedure allows cancer patients to reduce or eliminate pain medication and continue their standard treatment and normal daily activities without pain. In addition to firsthand accounts from patients and physicians, the site includes helpful questions and answers and a “locate a physician” feature to connect patients with doctors who perform the procedure in their area.
“The pain in my back kept me from living. It hurt to bend over or twist. I couldn’t lift anything. Because I had reached the maximum dose and couldn’t have any more radiation therapy in my spine, I needed to find something else,” said Kathryn, a colorectal cancer patient, whose story is featured on the site. “After the surgery, I felt a difference right away. I was amazed. It’s really changed my life.”
“This site is an excellent resource for patients seeking more information on the latest advancements in the treatment of painful spinal tumors,” said Dr. Sandeep Bagla, an interventional radiologist at Inova Alexandria Hospital. “This targeted RF ablation procedure allows patients to have their pain from spinal tumors alleviated so they can focus their energy on battling their underlying disease.”
About DFINE, Inc.
DFINE is a privately held company based in San Jose, CA., dedicated to relieving pain and improving the quality of life for patients suffering from spinal diseases through innovative, minimally invasive therapies. For more information visit www.dfineinc.com.
DFINE is a registered trademark and Targeted Radiofrequency Ablation (t-RFA) is a trademark of DFINE, Inc.
The STAR™ Tumor Ablation System does not treat cancer. It is commercially cleared by the FDA for providing palliative treatment (i.e., pain relief) by ablation of metastatic malignant tumors in a vertebral body. Patients undergoing radiofrequency ablation are subject to risks associated with surgery including complications from anesthesia/sedation as well as bleeding, bruising, pain and infection. Additional complications could include: blood clots, collapsed lungs, and damage to normal tissue, nerves, the spinal cord or other structures resulting in injuries including paralysis. Not every patient is a good candidate for the STAR™ Tumor Ablation System. The STAR System is contraindicated for patients with pacemakers or other electronic implants, and for the cervical section of the spine. Every patient is different and you should discuss potential risks and benefits of the procedure, including recovery time, with your physician.